GlassScriptPhysician profile
Richard L Smith
NPI 1861448664
$3,383.97
in general payments reported to CMS, 2019-2025
40 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $73.50 · 2021: $380 · 2022: $402 · 2023: $662 · 2024: $729 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $608.86 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $344.53 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $326.69 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Otsuka America Pharmaceutical, INC. | $211.21 | 2023-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.50 | 2023-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.14 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $138.08 | 2020-2025 | |
| Astellas Pharma US INC | $118.07 | 2023-2025 | Veozah |
| Amgen INC. | $114.62 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $102.89 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $99.38 | 2022-2024 | Austedo, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $84.48 | 2019-2025 | Invega Sustenna |
| Sanofi-Aventis U.S. LLC | $77.54 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $66.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $65.69 | 2019-2025 | Vaxneuvance, Vaxelis, M-M-R II |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.